ESTRO 2024 - Abstract Book

S1196

Clinical - Head & neck

ESTRO 2024

Results:

1,655 (88%) patients completed treatment in time, 180 (10%) patients had late completion and 42 (2%) patients did not complete their treatment. Cardiovascular (40%), respiratory (14%), and endocrine (11%) conditions were the most common comorbidities. Overall comorbidity scores showed almost half of patients had no comorbidity (46%), and 35%, 14% and 5% of patients had mild, moderate, and severe comorbidity burdens, respectively. An adjusted multivariable Cox model showed that those patients who did not complete treatment had worse survival than those that completed treatment in time (HR (95% confidence interval (CI)) = 3.32 (1.84, 5.99), P < 0001), Figure 1. The risk of not completing treatment increased for patients with moderate (OR (95%) = 12.48 (2.84, 54.77), P = 0.001), and severe overall comorbidity scores (OR (95%) = 8.26 (1.14, 59.7), P = 0.036). No significant association was found between the risk of late completion and overall comorbidity scores. The risk of not completing treatment increased for patients with cardiovascular conditions at baseline (OR (95%) = 6.39 (2.13, 19.19), P = 0.001), Figure 2. The risk of late completion was not significantly associated with other comorbidities in our cohort. An adjusted multinomial logistic regression with interaction of cardiovascular and respiratory comorbidities indicated the risk of late treatment completion increased for patients with both respiratory and cardiovascular comorbidities (OR (95%) = 5.03 (1.05, 24.07), P = 0.04), Figure 2.

Conclusion:

In this cohort of HNSCC cancer patients treated with curative intent (chemo) radiotherapy, treatment completion was associated with improved OS, but late completion had no effect. Risk of not completing RT is associated with increasing comorbidity score, regardless of late completion. Individual comorbidities are associated with treatment completion. Risk of not completing was associated with presence of cardiovascular comorbidities and risk of late treatment completion was associated with the presence of both respiratory and cardiovascular comorbidities.